Results of 2 phase I studies of intravenous (iv) pelitrexol (AG2037), a glycinamide ribonucleotide formyltransferase (GARFT) inhibitor, in patients (pts) with solid tumors. JCO 22 , 3075-3075 (2004).

In response, researchers have focused on N-acryloyl glycinamide (NAGA)-derived polymers, which harness the power of multiple hydrogen bonds and offer remarkable tunability in their properties.